EUROFINS SCIENTIFIC : Eurofins signs an exclusive agreement with the Fondation Institut Pasteur de Lille towards a partnership in the environmental testing field
20 July, 2011
Eurofins Scientific announces that it has signed an agreement on the 19th of July, 2011 to enter into exclusive discussions with the Fondation Institut Pasteur de Lille towards a partnership including the acquisition of its subsidiaries, IPL Invest and IPL Santé Environnement Durable Nord (IPL SED Nord). These entities are active in the environmental testing market in France, and together generated in excess of EUR 40m in revenues in 2010.
With more than 10 laboratories across France, IPL Invest and IPL SED Nord boast a large portfolio of accreditations and solid reputation in the French environmental testing market, and in particular, in water testing. Therefore, the acquisition would reinforce Eurofins' position as a leading service provider in the French environmental testing market
For further information please contact:
Investor Relations and Corporate Communications
Phone: +32-2-769 7383
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With about 9,500 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.
The Eurofins Group is the world leader in food and environmental testing and one of the global market leaders in pharmaceuticals testing. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Activité de l'émetteur (acquisitions, cessions...) Communiqué intégral et original au format PDF :
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free